about
Clinical evidence of efficacy of red yeast rice and berberine in a large controlled study versus diet.Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trialInsufficient control of blood pressure and incident diabetesFunctional foods and cardiometabolic diseases* International Task Force for Prevention of Cardiometabolic Diseases.Cardiovascular ultrasound exploration contributes to predict incident atrial fibrillation in arterial hypertension: the Campania Salute Network.Prevalence and characteristics of true and apparent treatment resistant hypertension in the Campania Salute Network.Nutraceuticals for treatment of high blood pressure values in patients with metabolic syndrome.Antihypertensive response to combination of olmesartan and amlodipine does not depend on method and time of drug administration.Association of suboptimal blood pressure control with body size and metabolic abnormalities.Identification of phenotypes at risk of transition from diastolic hypertension to isolated systolic hypertension.A single blind, multicenter, randomized controlled trial to evaluate the effectiveness and cost of a novel nutraceutical (LopiGLIK) lowering cardiovascular disease riskShould Thiazide Diuretics be Given as First Line Antihypertensive Therapy or in Addition to Other Medications?Risk factors and acute ischemic stroke subtypesCardiovascular risk in relation to a new classification of hypertensive left ventricular geometric abnormalitiesPersistence and adherence to antihypertensive treatment in relation to initial prescriptionSmoking Selectively Accelerates Carotid Atherosclerosis in Hypertensive Patientsβ2-Adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertensionDoes Information on Systolic and Diastolic Function Improve Prediction of a Cardiovascular Event by Left Ventricular Hypertrophy in Arterial Hypertension?
P50
Q35151507-059CF4D3-6DAE-4134-9A52-703ADEB4341EQ35708669-CC3298F3-3E5B-4F45-BCD4-CF38EFCE3871Q37163767-21F2DA8F-822D-4AFF-A8C5-0983529BD13CQ38281691-77D9B5E6-D092-4BB6-B5E9-E6D3E868EDC0Q41540096-A8CF3D27-01D2-4A66-A5D2-5FC26F9E1BE6Q44059286-1C552A93-2DB2-47AC-A337-D01CBA524D7CQ44809833-62BB4E43-0133-4EFA-82F1-120A8DD687F8Q45137855-BF6EB5C0-139F-4E77-8D0D-B340F750CC1AQ47267021-994814F1-C938-4EC7-B677-DE32DB383F0AQ48135297-EE5DDEBE-6017-4363-BF94-1E9F217B9C3FQ57817370-6C7FA7E1-B64F-480C-AD1A-6DC4E7E160C2Q59184108-4A340ABE-89BD-41E1-9298-92138FAB973FQ60647406-7390AA01-A44A-4E3A-9690-51C521D12E41Q61800196-82640351-5D3D-4285-B28E-872446B7F197Q61800269-83F8489F-9A37-495F-9713-B6A79C081CACQ61800304-7597C3E4-5B57-45C6-8B87-9F92E43F5852Q61800318-9AEAAD27-04DB-4F82-8DCD-59C2F7BA6D54Q61868236-76EFAD4F-6BF6-4F9C-99C9-22754A1181EF
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Francesco Rozza
@ast
Francesco Rozza
@en
Francesco Rozza
@es
Francesco Rozza
@nl
Francesco Rozza
@sl
type
label
Francesco Rozza
@ast
Francesco Rozza
@en
Francesco Rozza
@es
Francesco Rozza
@nl
Francesco Rozza
@sl
prefLabel
Francesco Rozza
@ast
Francesco Rozza
@en
Francesco Rozza
@es
Francesco Rozza
@nl
Francesco Rozza
@sl
P106
P1153
23498918300
P21
P31
P496
0000-0002-6631-6230